Research and Markets has announced the addition of the "Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H2 2016" report to their offering.

Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H2 2016', provides in depth analysis on Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted pipeline therapeutics.

The report provides comprehensive information on the Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics development and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Mitogen Activated Protein Kinase 8 Overview
  3. Therapeutics Development
  4. Pipeline Products for Mitogen Activated Protein Kinase 8 - Overview
  5. Pipeline Products for Mitogen Activated Protein Kinase 8 - Comparative Analysis
  6. Mitogen Activated Protein Kinase 8 - Therapeutics under Development by Companies
  7. Mitogen Activated Protein Kinase 8 - Therapeutics under Investigation by Universities/Institutes
  8. Mitogen Activated Protein Kinase 8 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Mitogen Activated Protein Kinase 8 - Products under Development by Companies
  13. Mitogen Activated Protein Kinase 8 - Products under Investigation by Universities/Institutes
  14. Mitogen Activated Protein Kinase 8 - Companies Involved in Therapeutics Development

- Celgene Corp

- Eisai Co Ltd

- OPKO Health Inc

For more information about this report visit http://www.researchandmarkets.com/research/6bmq2s/mitogen_activated